White & Case (Washington)

Adam Acosta

White & Case (Washington)
Lawyer (Associate)

Adam Acosta is an associate in the Firm’s Global Antitrust and Competition Practice. His practice focuses on antitrust litigation, government investigations, and related counseling. Mr. Acosta represents clients in a wide range of industries and frequently represents clients in the pharmaceutical industry with cases involving allegations of reverse payment settlements and product hopping. Prior to joining White & Case, Mr. Acosta completed a two-year clerkship in the US District Court for the Southern District of Indiana. He currently serves as an elected board member for the Hispanic Bar Association of DC and is active in the American Bar Association’s Antitrust Section.

Distinctions

Auteurs associés

White & Case (Brussels)
White & Case (New York)
White & Case (Washington)
White & Case (New York)
White & Case (Brussels)

Articles

504 Bulletin

Mark J. Gidley, George Paul, Rebecca H. Farrington, Martin M. Toto, Kathryn Jordan Mims, Michael E. Hamburger, Daniel Rosenthal, Adam Acosta, Jaclyn Phillips The US State of New York Senate adopts a legislation prohibiting the abuse of dominance and requiring new thresholds for the State’s pre-merger notification system

190

While Congress has been the epicenter of an ongoing antitrust debate—with US legislators on both sides of the aisle urging vast reforms—the New York State legislature is pursuing a state bill that would arguably ensnare more conduct and transactions in antitrust law’s web than anything proposed, (...)

Bryan D. Gant, Eric Grannon, Adam Acosta The US District Court for the District of Delaware contradicts the Supreme Court precedent regarding patent settlements in the pharmaceutical sector (Chimicles Schwartz Kriner / Donaldson-Smith / Amgen / Teva / Watson / Actavis)

61

A Nov. 30 decision by the U.S. District Court for the District of Delaware, In re : Sensipar Antitrust Litigation, contradicts controlling U.S. Supreme Court precedent and, if followed, could have significant implications for patent settlements well outside the pharmaceutical context in which (...)

Adam Acosta, Eric Grannon The US FTC and the FDA issue a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive practices in the biologic marketplace

87

On February 3, 2020, the Federal Trade Commission ("FTC") and the Food and Drug Administration ("FDA") issued a joint statement and plan seeking to advance biosimilar competition and combat deceptive and anticompetitive practices in the "biologic marketplace." As discussed below, the FTC and (...)

Envoyer un message